NCT06563323View on ClinicalTrials.gov

Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

August 13, 2027

Study Completion Date

August 13, 2027

Conditions
Pyoderma GangrenosumSkin DiseasesWound HealPyodermaSkin Ulcer
Interventions
DRUG

Guselkumab

Subjects with PG will be treated with 100 mg in a pre-filled syringe to be injected subcutaneously every 4 weeks for 28 weeks.

Trial Locations (1)

97239

Oregon Health and Science University, Portland

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

collaborator

Ohio State University

OTHER

lead

Oregon Health and Science University

OTHER